HIV reverse transcriptase and HIV integrase — Drug Target

All drugs that target HIV reverse transcriptase and HIV integrase — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Antiretroviral combination therapy (NRTI/NtRTI + INSTI) · Antiretroviral combination therapy (NRTI + INSTI)

Marketed (2)

• Tenofovir, Emtricitabine, Raltegravir · Hospital Clinic of Barcelona · Antiretroviral combination therapy (NRTI/NtRTI + INSTI) · Infectious Disease / Virology
  This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing viral DNA synthesis and integration into the host genome.
• TRUVADA + Raltegravir · Fenway Community Health · Antiretroviral combination therapy (NRTI + INSTI) · Infectious Disease / Virology
  This combination blocks HIV replication by inhibiting reverse transcriptase (TRUVADA) and integrase (raltegravir), preventing the virus from copying itself and integrating into host DNA.